Randomized Trialhigh evidence
Randomized, sham-controlled trial of intraoperative ticagrelor removal to reduce perioperative bleeding.
The Journal of thoracic and cardiovascular surgery·July 1, 2026·PMID 41581856
Why it mattersPatients requiring urgent cardiac surgery while on ticagrelor face high bleeding risk due to residual antiplatelet effects. A safe intraoperative drug removal strategy could mitigate this risk, potentially reducing transfusions and reoperations, especially in isolated CABG where the benefit was most evident.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled